Results 91 to 100 of about 6,619 (182)

Comparison of the change in annual growth rate of total kidney volume between the tolvaptan group and the non-tolvaptan group in patients including the history of physical interventions for polycystic liver.

open access: yes, 2022
The median difference in the annual growth rate in total kidney volume (TKV) was larger in the tolvaptan group (0.2 (-42.0, 50.9)) than in the non-tolvaptan group (1.1 (-55.0, 23.4)) (p = 0.02, Wilcoxon rank sum test). Abbreviation.
Akinari Sekine (4357189)   +8 more
core   +1 more source

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)

open access: yesESC Heart Failure, 2020
Aims Hyponatremia is associated with poorer outcomes and diuretic response in patients hospitalized for heart failure. This study compared a tolvaptan‐based vs.
Tien M.H. Ng   +9 more
doaj   +1 more source

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

open access: yes, 2021
(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed.
Atsushi Hosui   +11 more
core   +1 more source

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

open access: yesPLoS ONE, 2017
AimsSeveral studies reported treatment benefits of tolvaptan in patients with congestive heart failure (CHF). However, the optimal dosage remains unclear.
Mei-Yi Wu   +6 more
doaj   +1 more source

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report

open access: yesCase Reports in Nephrology and Dialysis, 2018
A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years.
Kyohei Kunizawa   +14 more
doaj   +1 more source

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients

open access: yes, 2010
Savina Nodari1, Geoffrey T Jao2, Jun R Chiong31Division of Cardiology, University of Brescia, Brescia, Italy; 2Section of General Internal Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA; 3Division of Cardiology, Loma ...
Savina Nodari   +2 more
core  

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload

open access: yes, 2018
Shunji Suzuki,1,2 Norio Hanafusa,3 Kenji Kubota,1 Ken Tsuchiya,3 Kosaku Nitta2 1Department of Nephrology, Kawaguchi Saiseikai Hospital, Kawaguchi, Japan; 2Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan ...
Tsuchiya K   +4 more
core  

Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites

open access: yes, 2019
To investigate the relationship between the exposure and efficacy of tolvaptan, we measured pharmacokinetics of total drug at 7 days after repeated doses of 3.75 mg/day tolvaptan in 16 patients with hepatic edema.
Eisuke Nakadera   +8 more
core   +1 more source

Sulfonate and acetyl derivatives of the vasopressin antagonist tolvaptan: reactivity towards DNA and 2’-deoxynucleosides [PDF]

open access: yes, 2016
Tolvaptan is an orally effective nonpeptide arginine vasopressin (AVP) V2-receptor antagonist, used in the treatment of clinically significant euvolemic and hypervolemic hyponatremia.
Fidalgo, Lara Gião
core  

Home - About - Disclaimer - Privacy